 Midatech Pharma NASDAQ:MTP is on a sweet spot this Friday as the business lifted the veil on its most recent clinical trial, yielding results that were commendable.Source: Shutterstock The United Kingdom-based biopharmaceutical organization said it brought in positive results after the first in-human study of its diabetes vaccine. The substance in questions is its MTX102 immuno-tolerising candidate that may have the potential of helping the lives of those who suffer from Type 1 diabetes.Midatechs early success in this matter propelled the brands trading volume forward as 2.9 million shares exchanged hands, which is many times higher than its full-day average of about 88,000 shares. The company conducted the study by bringing forth five Type 1 diabetes patients in the phase 1 study-this study was designed to determine the safety of MTX102.InvestorPlace - Stock Market News, Stock Advice Trading TipsMTX102 was well tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported, the company wrote.MTP stock is up about 30.8 during regular trading hours today following this news, lifting the share price to 1.70 per share after starting the day with a price of 1.30 per share. Midatech now has a market cap of roughly 32.46 million.However, the MTP per-share price is still far from its 2019 peak of 7.90 that it experienced back in February 27. More From InvestorPlace 10 Tech Stocks That Are Still Worth Your Time And Money 7 Stocks Top Investors Are Buying Now 9 Retail Stocks Goldman Sachs Says Are Ready to Rip 10 Stocks to Sell for an Economic Slowdown The post Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results appeared first on InvestorPlace. 